{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002757","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.015486+00:00","generated_at":"2026-05-16T10:54:18.985879+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Scholar Rock provides 2026 priorities; ~$365M cash; apitegromab BLA resubmission expected in 2026","bullets":["Preliminary cash of ~$365M as of Dec 31, 2025; expected runway into 2027.","Apitegromab BLA resubmission for SMA anticipated in 2026; U.S. launch expected after FDA approval.","IND cleared for FSHD; Phase 2 FORGE trial initiation and dosing expected mid-2026.","Subcutaneous apitegromab Phase 1 completed; SRK-439 Phase 1 topline data expected H2 2026.","EMA MAA decision for apitegromab expected mid-2026; second U.S. fill-finish facility capacity reserved."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002757","json":"https://secwatch.observer/filing/0001104659-26-002757.json","markdown":"https://secwatch.observer/filing/0001104659-26-002757.md","text":"https://secwatch.observer/filing/0001104659-26-002757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/0001104659-26-002757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:18.985879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}